MAY 18, 2021 8:00 AM PDT

A Silver Bullet Against COVID Variants?

WRITTEN BY: Tara Fernandez

Canadian researchers have discovered an antiviral drug that blocks the SARS-CoV-2 virus from infecting lung cells. Promisingly, the small molecule drug known as N-0385 was shown to be highly effective against new emerging threats, the SARS-CoV-2 variants of concern.

“In this study, we report a novel and highly potent small-molecule drug called N-0385, that acts as the most effective entry inhibitor to date,” said lead researcher Dr. François Jean, a microbiologist at the University of British Columbia. 

“We demonstrate that N-0385 is broadly protective against infection and mortality in mice, and believe N-0385 has potential as a viable early treatment option against emerging SARS-CoV-2 VOCs.”

Genetic variants of SARS-CoV-2 have begun to spread globally, with those displaying traits such as increased transmissibility, the ability to cause more severe COVID symptoms, and being able to evade vaccines and therapeutics classified as variants of concern. These include B.1.1.7 (first identified in the United Kingdom) and the B.1.351 variant (first isolated in South Africa). 

In the study, uploaded onto the preprint server BioRxiv, Jean and colleagues showed that the broad spectrum antiviral N-0385 was able to stop the B.1.1.7 and B.1.351 variants from entering cultured human lung cells. 

“N-0385 works by blocking TMPRSS2, an enzyme responsible for cutting and priming the viral spike protein so that it can attach and fuse with the host cell membrane, and release the virus’s genetic material,” explained Jean.

In animal studies, daily doses of N-0385 administered in the nose were shown to significantly increase the chances of survival in SARS-CoV-2-infected mice, without any detectable side effects.

“We hope that this, and related drugs, may have broader applications in combating other respiratory viruses that use the same means of entry into host cells, including established coronaviruses, influenza, and other viruses,” concludes Jean.

 


Sources: BioRxiv, University of British Columbia.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
FEB 07, 2021
Microbiology
Positive Results From A Clinical Trial of an HIV Vaccine
FEB 07, 2021
Positive Results From A Clinical Trial of an HIV Vaccine
After years of effort, researchers are reporting that there were encouraging results from a phase 1 clinical trial which ...
MAR 25, 2021
Immunology
The Immune System Impairs Antibiotic Effectiveness
MAR 25, 2021
The Immune System Impairs Antibiotic Effectiveness
Nitric oxide, a molecule produced by the immune system, can negatively impact antibiotics’ effectiveness, says a s ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 16, 2021
Microbiology
A New Kind of COVID-19 Vaccine
APR 16, 2021
A New Kind of COVID-19 Vaccine
The current COVID-19 vaccines by Pfizer/BioNTech and Modern are based on messenger RNA, which cells use to make proteins ...
JUN 01, 2021
Immunology
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
JUN 01, 2021
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
Seasonal flu vaccines only work around 40 to 60 percent of the time, says the U.S. Centers for Disease Control and Preve ...
Loading Comments...